Cargando…
A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
• Research surrounding treatment of leiomyosarcoma (LMS) treatment remains sparse. • Pembrolizumab/lenvatinib has been reported as a therapy for endometrial cancer, though not yet as therapy for LMS. • This report demonstrates disease regression after use of pembrolizumab and lenvatinib in a patient...
Autores principales: | Mehta, Naaman, Lee, Sarah S., Salame, Ghadir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932649/ https://www.ncbi.nlm.nih.gov/pubmed/36818196 http://dx.doi.org/10.1016/j.gore.2023.101145 |
Ejemplares similares
-
Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022) -
Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report
por: Alcindor, Thierry, et al.
Publicado: (2021) -
Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
por: Hunt, Jonathan T., et al.
Publicado: (2021) -
Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report
por: Liu, Zhaonan, et al.
Publicado: (2019) -
Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature
por: Wang, Yannan J., et al.
Publicado: (2021)